Medifast Q1 revenue falls as active coach count drops

ReutersMay 4, 2026 8:17 PM

View all comments（0）



Overview

U.S. metabolic health firm's Q1 revenue fell 34% yr/yr as active coach count declined
Company posted Q1 net loss of $2.1 mln, wider than prior year period
Medifast expects further coach declines and continued losses through 2026

Outlook

Company expects Q2 2026 revenue between $60 mln and $80 mln
Medifast sees Q2 2026 loss per share of $0.50 to $1.00
Company expects full-year 2026 revenue between $270 mln and $300 mln
Medifast sees 2026 loss per share of $1.55 to $2.75
Company expects number of active earning coaches to continue to decline in 2026

Result Drivers

COACH DECLINE - Revenue drop was primarily driven by a 45% decrease in active earning coaches, reflecting continued client acquisition challenges and increased use of GLP-1 weight loss drugs
HIGHER PRODUCTIVITY PER COACH - Revenue per active earning coach rose 19% as company prioritized productive coaches and efficient network structures
LOWER SALES VOLUME - Gross profit and margin declined due to lower sales volumes and loss of leverage on fixed costs

Company press release: ID:nBwC36jLa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue		$76.04 mln
Q1 EPS		-$0.19
Q1 Net Income		-$2.12 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Trump’s China Visit Boosts China Stocks Nearly 4%, Alibaba Favored by AI Bets Despite Weak Results

TradingKey - On May 13 (ET), U.S. President Trump arrived in Beijing to begin a three-day visit. Markets expect both sides to engage in dialogue on issues such as trade and technology, a move that has eased concerns over a further escalation of U.S.-China tensions.

Pricing Hiked Three Times to $185. What Gives Cerebras Confidence in Its $49B Valuation After Spurning SoftBank?

TradingKey - AI chipmaker Cerebras Systems is racing toward a US IPO with momentum far exceeding expectations, as Wall Street's fervor for the AI semiconductor sector is fully reflected in the company.

AI Frenzy vs. Crypto Winter: Cerebras Sets Year’s Largest IPO as Crypto Funding Hits Freezing Point

Market capital is exhibiting a powerful "siphon effect," as funds flow continuously toward AI hardware and infrastructure with clearer technological pathways and more defined revenue models. Conversely, the cryptocurrency sector has fallen out of favor due to the absence of these attributes. This suggests that if crypto enterprises can integrate AI development—such as the AI agent economy—they may have an opportunity to break through the current IPO freeze.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools